Findings

What do systematic reviews say?

416 questions · 426 findings · 56 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 109 · 25.6%GRADE not reported 23 · 5.4%Very low 109 · 25.6%Low 106 · 24.9%Moderate 64 · 15%High 15 · 3.5%

Summary of findings table ‐ Two puffs of cervical lidocaine spray vs placebo cervical spray/no spray

Pain during procedurea,b · people requesting a surgical abortion at 5+0 to 7+0 weeks' gestation

1 finding from 1 review

Local anaesthesia for pain control in first trimester surgical abortion 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

Summary of findings table ‐ 20 mL 1% lidocaine paracervical block vs normal saline paracervical block

Pain during procedure ‐ not measured · people requesting a surgical abortion at 13+6 weeks' gestation or less (Chin 2020 included people experiencing an early pregnancy loss)

The review found no eligible studies for this question.

1 finding from 1 review

Local anaesthesia for pain control in first trimester surgical abortion 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Sucrose (any concentration, any dose) vs expressed breast milk

PIPP‐R scores during heel lancing (preterm infants)Scale from: 0 to 21a,b · neonates

1 finding from 1 review

Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs laser acupuncture

NIPS scores during heel lancing (term infants)Scale from: 0 to 7a,b · neonates

1 finding from 1 review

Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs facilitated tucking

BPSN scores during heel lancing (preterm infants)Scale from: 0 to 27a,b · neonates

1 finding from 1 review

Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs facilitated tucking

BPSN scores during recovery after heel lancing (preterm infants)Scale from: 0 to 27a,e · neonates

1 finding from 1 review

Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
Very low

Summary of findings table ‐ Sucrose (any concentration, any dose) vs NNS

PIPP ‐ Preterm infants · neonates

1 finding from 1 review

Sucrose analgesia for heel‐lance procedures in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

Summary of findings table ‐ 2 site (4‐8 o?clock) paracervical block vs 4 site (2‐4‐8‐10 o?clock) paracervical block

Pain during procedure ‐ not measured · people requesting a surgical abortion at less than 11 weeks' gestation (Renner 2016) and seven to 12 weeks' gestation (Glantz 2001)

The review found no eligible studies for this question.

1 finding from 1 review

Local anaesthesia for pain control in first trimester surgical abortion 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Shift duration of no more than 16 hours vs shift duration of 24 to 28 hours

Sleepiness during shifts · Shift workers

1 finding from 1 review

Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 716 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
High

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low